Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation

Bibliography

• Available from: www.europeanaidsclinicalsociety.org/guidelines.asp
   Google Scholar
• Available from: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-33
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother 2004;15:121-34
   PubMedGoogle Scholar
• Gazzard B, Bernard AJ, Boffito M, British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503
   PubMed Web of Science ®Google Scholar
• Descamps D, Flandre P, Calvez V, Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA 2000;283:205-11
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Perry S, Charlebois ED, Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3
   PubMed Web of Science ®Google Scholar
• Garcia de Olalla P, Knobel H, Carmona A, Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Massari V, Descamps D, Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004;38:1311-6
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Das-Douglas M, Massari V, Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 2008;3:e2783
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Rohban R, Simon A, Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-8
   PubMed Web of Science ®Google Scholar
• Bacheler L, Jeffrey S, Hanna G, Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008
   PubMed Web of Science ®Google Scholar
• Antinori A, Zaccarelli M, Cingolani A, Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:835-8
   PubMed Web of Science ®Google Scholar
• Perrin L, Kaiser L, Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003;3:22-7
   PubMed Web of Science ®Google Scholar
• Andries K, Azijn H, Thielemans T, TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-6
   PubMed Web of Science ®Google Scholar
• Janssen PA, Lewi PJ, Arnold E, In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005;48:1901-9
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-27
   PubMed Web of Science ®Google Scholar
• Corbau R, Mori J, Phillips C, Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2010;54:4451-63
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009;48:484-8
   PubMed Web of Science ®Google Scholar
• Laurent C, Kouanfack C, Koulla-Shiro S, Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004;364:29-34
   PubMed Web of Science ®Google Scholar
• Frampton JE, Croom KF. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs 2006;66:1501-12; discussion 1513-14
   PubMed Web of Science ®Google Scholar
• Merluzzi VJ, Hargrave KD, Labadia M, Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-13
   PubMed Web of Science ®Google Scholar
• Montaner JS, Reiss P, Cooper D, A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-7
   PubMed Web of Science ®Google Scholar
• Smerdon SJ, Jager J, Wang J, Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994;91:3911-15
   PubMed Web of Science ®Google Scholar
• Esnouf R, Ren J, Ross C, Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995;2:303-8
   PubMedGoogle Scholar
• Zhang H, Dornadula G, Wu Y, Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virol 1996;70:628-34
   PubMed Web of Science ®Google Scholar
• Koup RA, Merluzzi VJ, Hargrave KD, Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991;163:966-70
   PubMed Web of Science ®Google Scholar
• Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-9
   PubMed Web of Science ®Google Scholar
• Cheeseman SH, Havlir D, McLaughlin MM, Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:141-51
   PubMedGoogle Scholar
• Raffi F, Bonnet B, Ferre V, Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000;31:1274-8
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Fenton T, Gagnier P, Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998;178:368-74
   PubMed Web of Science ®Google Scholar
• Havlir D, Cheeseman SH, McLaughlin M, High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45
   PubMed Web of Science ®Google Scholar
• Rotger M, Colombo S, Furrer H, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15:1-5
   PubMedGoogle Scholar
• Penzak SR, Kabuye G, Mugyenyi P, Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007;8:86-91
   PubMed Web of Science ®Google Scholar
• Mahungu T, Smith C, Turner F, Cytochrome P450 2B6 516G–>T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med 2009;10:310-17
   PubMed Web of Science ®Google Scholar
• Ritchie MD, Haas DW, Motsinger AA, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006;43:779-82
   PubMed Web of Science ®Google Scholar
• Haas DW, Bartlett JA, Andersen JW, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006;43:783-6
   PubMed Web of Science ®Google Scholar
• Veldkamp AI, Weverling GJ, Lange JM, High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-95
   PubMed Web of Science ®Google Scholar
• Macha S, Yong CL, Darrington T, In vitro-in vivo correlation for nevirapine extended release tablets. Biopharm Drug Dispos 2009;30:542-50
   PubMed Web of Science ®Google Scholar
• Battegay ME, Arasteh K, Plettenberg A, Assessment of the steady-state PK parameters of two extended release (XR) nevirapine (NVP) tablets 400 mg and 300 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1-infected patients – the ERVIR study [abstract PE4.1/2]. 12th Eur AIDS Conf (EACS); 11 – 14 November 2009; Cologne
   Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63
   PubMed Web of Science ®Google Scholar
• Soriano V, Koeppe S, Mingrone H, Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results [abstract LBPEB07]. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS); 19 – 22 July 2009; Cape Town, South Africa
   Google Scholar
• DeJesus E, Mills A, Bhatti L, Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data. J Int AIDS Soc 2010;13(Suppl 4):P4
   PubMedGoogle Scholar
• Gathe J, Knecht G, Orrell C, 48 Week efficacy, pharmacokinetics and safety of once a day 400 mg nevirapine extended release formulation for treatment of antiretroviral naive HIV-1 infected patients (VERxVE) [abstract H-1808]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September 2010; Boston
   Google Scholar
• Negredo E, Cruz L, Paredes R, Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10
   PubMed Web of Science ®Google Scholar
• Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. HIV Med 2008;9:747-56
   PubMed Web of Science ®Google Scholar
• Martinez E, Arnaiz JA, Podzamczer D, Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-46
   PubMed Web of Science ®Google Scholar
• Arasteh K, Ward D, Plettenberg A, 48 Wk efficacy and safety of switching virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION). 10th International Congress on Drug Therapy in HIV Infection; 7 – 11 November 2010; Glasgow
   Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,20933s014lbl.pdf
   Google Scholar
• Kesselring AM, Wit FW, Sabin CA, Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009;23:1689-99
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Verdon R. Nevirapine and cardiovascular risk. Med Mal Infect 2010;40:499-505
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005;19:1051-8
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Massari V, Rey D, Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis 2007;45:263-6
   PubMed Web of Science ®Google Scholar
• Sankatsing RR, Wit FW, Pakker N, Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis 2007;196:15-22
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA, Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35
   PubMed Web of Science ®Google Scholar
• Phillips AN, Carr A, Neuhaus J. Interruption of ART and risk of cardiovascular disease:findings from SMART [abstract 41]. 14th Conference on Retroviruses and Opportunistic Infection (CROI); 25 – 28 February 2007; Los Angeles
   Google Scholar
• Clotet B, van der Valk M, Negredo E, Reiss P. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S79-84
   PubMedGoogle Scholar
• Lundgren JD, Reiss P, Worm S. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: The D:A:D study [abstract 44LB]. 16th Conference on Retroviruses and Opportunistic Infections (CROI); 8 – 11 February 2009; Montreal, Canada
   Google Scholar
• Letendre S, Ellis R, Deutsch R, ; and the Charter group. Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER Cohort [abstract 430]. Seventeenth Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010
   Google Scholar
• Bonora S, Nicastri E, Calcagno A, Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009;81:400-5
   PubMed Web of Science ®Google Scholar
• Haim-Boukobzai S, Morand-Joubert L, Flandre P, Residual plasma viraemia below 40 copies/ml under NNRTI-based regimen [abstract 134]. International HIV and Hepatitis Drug Resistance Workshop; 8 – 12 June 2010; Dubrovnik, Croatia
   Google Scholar
• Reliquet V, Allavena C, Morineau-Le Houssine P, Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients. HIV Clin Trials 2010;11:110-17
   PubMed Web of Science ®Google Scholar
• Elzi L, Marzolini C, Furrer H, Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010;170:57-65
   PubMed Web of Science ®Google Scholar
• Willig JH, Abroms S, Westfall AO, Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008;22:1951-60
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Massari V, Reliquet V, Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. AIDS 2007;21:2217-22
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, James I, Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-9
   PubMed Web of Science ®Google Scholar
• Vitezica ZG, Milpied B, Lonjou C, HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008;22:540-1
   PubMed Web of Science ®Google Scholar
• Rodriguez-Arrondo F, Aguirrebengoa K, Portu J, Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. Curr HIV Res 2009;7:526-32
   PubMed Web of Science ®Google Scholar
• Schouten JT, Krambrink A, Ribaudo HJ, Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010;50:787-91
   PubMed Web of Science ®Google Scholar